
HIMS Stock Forecast & Price Target
HIMS Analyst Ratings
Bulls say
Hims & Hers Health is expected to see continued growth in subscribers and revenue, with a focus on international expansion. However, there are concerns about margin and investment challenges, as well as potential regulatory risks and competition in the GLP-1 market. The recent partnership with Novo Nordisk and strong outlook for revenue by 2030 provide a positive outlook, but the company must carefully manage economics and customer retention to sustain growth and justify investments.
Bears say
Hims & Hers Health is facing a number of challenges and concerns that are contributing to a negative outlook from financial analysts. These concerns include slow revenue growth, declining margins, competition from larger players and venture-backed startups, and the potential impact of tighter regulations on its compounding businesses. Additionally, while its weight loss segment is currently a key driver of growth, there are risks associated with entering the competitive GLP-1 market. While the recent partnership with Novo Nordisk may provide some relief from these challenges, there are still uncertainties and risks ahead for Hims & Hers Health.
This aggregate rating is based on analysts' research of Hims & Hers Health and is not a guaranteed prediction by Public.com or investment advice.
HIMS Analyst Forecast & Price Prediction
Start investing in HIMS
Order type
Buy in
Order amount
Est. shares
0 shares